Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238 | 0.75 | KMT2A (0.41) | KMT2ACYP2D6LMNA | |
| SCHEMBL7327576 | 0.75 | KMT2A (0.41) | KMT2ACYP2D6LMNA | |
| SCHEMBL2646405 | 0.75 | CYP3A4 (0.46) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6629617 | 0.74 | CFTR (0.48) | SLC6A2SLC6A4SLC6A3CYP19A1GAA | |
| SCHEMBL12784512 | 0.73 | SLC6A2 (0.46) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9129250 | 0.73 | SLC6A2 (0.46) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17011305 | 0.73 | SLC6A2 (0.46) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL183928 | 0.72 | — | — | |
| SCHEMBL16798444 | 0.71 | SLC6A4 (0.48) | SLC6A2SLC6A4SLC6A3CYP19A1MEN1 | |
| SCHEMBL4196376 | 0.71 | AOC3 (0.44) | CYP2C19SLC6A2SLC6A4SLC6A3CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100360580-C | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVENTIS PHARM PROD INC (US) | 2008-01-09 | — | — | CN | disclosed |
| CN-1769318-A | Polymeric resin compounds and their preparation | AVENTIS PHARM PROD INC (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1754899-A | Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVENTIS PHARM PROD INC (US) | 2006-04-05 | — | — | CN | disclosed |
| CN-1238323-C | Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | AVENTIS PHARMA INC (US) | 2006-01-25 | — | — | CN | disclosed |
| CN-1235925-C | Solid phase synthesing method of aldehyde, ketonic, oxime amine and isohydroximic acid compound | AVENTIS MEDICINE CORP (US) | 2006-01-11 | — | — | CN | disclosed |
| CN-1185259-C | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2005-01-19 | — | — | CN | disclosed |
| CN-1173946-C | Method for preparing an N-[(aliphatic or aromatic) carbonyl]-2-aminoacetamide compound and a cyclyzed compound | ���µ�˹ҩ�﹫˾ | 2004-11-03 | — | — | CN | disclosed |
| CN-1173938-C | Alpha-substitution of unprotected beta-amino ester compounds | ���µ�˹ҩ�﹫˾ | 2004-11-03 | — | — | CN | disclosed |
| CN-1500769-A | Process for the solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | ���µ�˹ҩ�﹫˾ | 2004-06-02 | — | — | CN | disclosed |
| CN-1496999-A | Solid phase synthesing method of aldehyde, ketonic, oxime amine and isohydroximic acid compound | ���µ�˹ҩ�﹫˾ | 2004-05-19 | — | — | CN | disclosed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| CN-1334799-A | Alpha-substitution of unprotected beta-amino ester compounds | AVENTIS PHARM PROD INC (US) | 2002-02-06 | — | — | CN | disclosed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
| CN-1307553-A | Solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha, beta-unsaturated carboxylic acid and aldehyde compounds | AVANTIES MEDICINE PRODUCT CO (US) | 2001-08-08 | — | — | CN | disclosed |
| CN-1306524-A | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2001-08-01 | — | — | CN | disclosed |
| CN-1289324-A | Method for preparing an N-[(aliphatic or aromatic) carbonyl]-2-aminoacetamide compound and a cyclyzed compound | AVENTIS PHARMA INC (US) | 2001-03-28 | — | — | CN | disclosed |
| CN-1240418-A | Solid phase synthesis of aldehydes, ketones, oximes, amines and hydroxamic acid compounds | RHONE POULENC RORER PHARMA (US) | 2000-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | CYP3A4 1294/4885CYP2C19 1255/4885SLC6A2 2830/4885 |
| US-20020032221-A1 | Pyrrole derivatives | PYCR1, SARS1, MAVS | CYP3A4 433/4885CYP2C19 1064/4885SLC6A2 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.